| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.oxygentapharma.com | |
| Market Cap | 126.74 Cr. | |
| Enterprise Value(EV) | 180.87 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -4.71 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.30 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | -8.59 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | -4.41 | Calculated using Price: 37.85 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 3.35 Cr. | 33,483,500 Shares |
| FaceValue | 10 | |
| About Oxygenta Pharmaceutical Ltd. | ||
| SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates. | ||
| 1 Day |
|
-3.22% |
| 1 Week |
|
-1.48% |
| 1 Month |
|
+32.85% |
| 3 Month |
|
+13.56% |
| 6 Month |
|
+30.29% |
| 1 Year |
|
+20.66% |
| 2 Year |
|
+61.06% |
| 5 Year |
|
+303.09% |
| 10 Year |
|
+425.69% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Return on Capital Employed (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.18 | -50.31 | |
| Return on Assets (%) | -33.71 | -29.05 | -29.92 | -25.13 | -17.07 | -29.1 | 11.16 | -1.88 | -27.09 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | -16 | -22 | -27 | -32 | -35 | -41 | -38 | -35 | -46 | -25 | |
| Non Curr. Liab. | 18 | 21 | 31 | 31 | 40 | 44 | 54 | 58 | 71 | 55 | |
| Curr. Liab. | 16 | 21 | 16 | 18 | 17 | 16 | 18 | 8 | 30 | 33 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 64 | |
| Non Curr. Assets | 13 | 14 | 13 | 13 | 12 | 12 | 18 | 22 | 29 | 32 | |
| Curr. Assets | 5 | 5 | 6 | 4 | 9 | 7 | 16 | 10 | 25 | 32 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 64 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 37 | |
| Other Income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||||
| Total Income | 6 | 12 | 9 | 14 | 21 | 14 | 52 | 61 | 31 | 37 | |
| Total Expenditure | -10 | -17 | -13 | -17 | -23 | -22 | -48 | -59 | -38 | -48 | |
| PBIDT | -4 | -4 | -4 | -3 | -2 | -8 | 4 | 1 | -7 | -10 | |
| Interest | 0 | -1 | -1 | -1 | -1 | -1 | -2 | -1 | -1 | -2 | |
| Depreciation | -3 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -3 | |
| Taxation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Exceptional Items | 4 | 2 | 1 | -1 | 0 | ||||||
| PAT | -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -16 | |
| Adjusted EPS | -6 | -5 | -6 | -4 | -3 | -6 | 3 | 0 | -8 | -6 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -3 | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | |
| Cash Fr. Inv. | -2 | 1 | -2 | -1 | 0 | -1 | -1 | -7 | -5 | -10 | |
| Cash Fr. Finan. | 4 | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | |
| Net Change | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Thu, 25 Apr 2024
Draft Letter of Offer Mark Corporate Advisors Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Equity Shareholders of Oxygenta Pharmaceutical Ltd ("Target Company"). |
|
Thu, 18 Apr 2024
Detailed Public Statement Mark Corporate Advisors Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Detailed Public Statement under Regulations 13(4) 14(3) and 15(2) of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended for the attention of the eligible Equity Shareholders of Oxygenta Pharmaceutical Ltd ("Target Company"). |
|
Mon, 15 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 With reference to the above we are enclosing the certificate dated 03.04.2024 issued by M/S Venture Capital and Corporate Investment Private Limited RTA of the company. |
| Wed, 24 Apr 2024 |
Opening at High
|
High Increase in 1 Month
|
High Increase in 3 Months
|
High Increase in 6 Months
|
High Increase in 2 Years
|
